These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22762423)

  • 1. New drugs for the treatment of tuberculosis: hope and reality.
    Grosset JH; Singer TG; Bishai WR
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1005-14. PubMed ID: 22762423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for tuberculosis treatment.
    Sánchez F; López Colomés JL; Villarino E; Grosset J
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():47-56. PubMed ID: 21420567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New tuberculosis drugs in resistant and multiresistant tuberculosis].
    Ramírez Lapausa M; Pascual Pareja JF; Noguerado Asensio A
    Med Clin (Barc); 2013 Oct; 141(7):306-13. PubMed ID: 23540388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century.
    Burman WJ
    Clin Infect Dis; 2010 May; 50 Suppl 3():S165-72. PubMed ID: 20397944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis: the drug development pipeline at a glance.
    Villemagne B; Crauste C; Flipo M; Baulard AR; Déprez B; Willand N
    Eur J Med Chem; 2012 May; 51():1-16. PubMed ID: 22421275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of tuberculosis: epidemiology, resistance and monitoring.
    Bang D
    Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs for tuberculosis.
    Grassi C; Peona V
    Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs.
    Abate G; Miörner H; Ahmed O; Hoffner SE
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):580-4. PubMed ID: 9661826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
    Di Perri G; Bonora S
    J Antimicrob Chemother; 2004 Sep; 54(3):593-602. PubMed ID: 15282233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.